Beta Drugs share news, announcements and annual reports
NSE: BETAPharmaceuticals & BiotechnologySmall Cap
Beta Drugs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2017 · Issue price ₹85
Last close ₹1,798.40down ₹51.30 (2.77%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,849.70.
30 Oct: open ₹1,880.60, high ₹1,880.60, low ₹1,790.60
52-week range of traded prices to 30 Oct 2026
₹990.10Low, 25 Feb 2026₹2,807.90High, 12 Aug 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,000 Cr1,305th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.57
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 16.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 23,66047.9% delivered
Beta Drugs share news and announcements
387 announcements, routine notices left out, newest first. Page 4 of 8.
Sep 2023
30 Sep · Meeting
1 Sep · Board meeting
Aug 2023
23 Aug · Analysts
May 2023
17 May · Legal
Exchange has sought clarification from Beta Drugs Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.8 May · Results
Apr 2023
26 Apr · Analysts
25 Apr · Board meeting
20 Apr · Updates
Mar 2023
Jan 2023
25 Jan · Updates
Oct 2022
21 Oct · Analysts
4 Oct · Meeting
1 Oct · Meeting
Sep 2022
29 Sep · Meeting
5 Sep · Meeting
Aug 2022
30 Aug · Meeting
30 Aug · Board meeting
Jul 2022
20 Jul · Board meeting
Jun 2022
16 Jun · Board meeting
May 2022
Apr 2022
28 Apr · Related Party Transaction
27 Apr · Results
22 Apr · Analysts
22 Apr · Analysts
12 Apr · General updates
Mar 2022
2 Mar · General updates
Feb 2022
7 Feb · Legal
Exchange has sought clarification from Beta Drugs Limited with respect to announcement dated 02-Feb-2022, regarding New Product Launches to drive growth for Beta Drugs. On basis of above the Company is required to clarify following:1. Date of launch;2. Whether caters to domestic/ international market;3. Name of the countries in which the product is launched (in case of international).The response of the Company is awaited.2 Feb · Updates
Jan 2022
31 Jan · Updates
24 Jan · Legal
Exchange has sought clarification from Beta Drugs Limited with respect to announcement dated 20-Jan-2022, regarding appointment of Mr. Ashutosh Shukla as Additional Director of the company. On basis of above you are required to clarify following - 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. The response of the Company is awaited.20 Jan · Board meeting
Dec 2021
Nov 2021
25 Nov · Analysts